Res. Asst. BAHAR ARSLAN

Publication Network

Articles 21

1. Interval prolongation is an effective and well-tolerated approach when stepping down omalizumab treatment in chronic spontaneous urticaria

KÖYLÜCE S., AÇAR E., ŞEKER S., Yilmaz H. E. B., Yapici E. A., ARSLAN B., et al.

ARCHIVES OF DERMATOLOGICAL RESEARCH , vol.317, no.1, 2025 (SCI-Expanded, Scopus)

2. What Does Radiologic Assessment Contribute to Asthma: A Subanalysis of the Turkish Adult Asthma Registry

KIZILIRMAK D., Uzun O., GÖKMEN D., AYDIN Ö., BAŞYİĞİT İ., DURSUN A. B., et al.

Bratislava Medical Journal , vol.126, no.6, pp.1008-1022, 2025 (SCI-Expanded, Scopus)

3. Asthma patients with obesity have a unique phenotype: a subanalysis of the Turkish adult asthma registry

ÇELEBİ SÖZENER Z., OĞUZÜLGEN İ. K., Ozalp Ates F. S., Baccioglu A., ARGUN BARIŞ S., EDİGER D., et al.

Journal of Asthma , vol.62, no.7, pp.1183-1194, 2025 (SCI-Expanded, Scopus)

4. Socioeconomic status has direct impact on asthma control: Turkish adult asthma registry

ARSLAN B., TÜRK M., HAYME S., AYDIN Ö., GÖKMEN D., Buhari G. K., et al.

Clinical and Translational Allergy , vol.15, no.1, 2025 (SCI-Expanded, Scopus) Sustainable Development

5. Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma? Mepolizumab: Hangi durum daha fazla fayda sağlar: Burun polipleri mi, eozinofilik astım mı?

AÇAR E., KÖYLÜCE S., ŞEKER S., BOZKURT YILMAZ H. E., AKTAŞ YAPICI E., ARSLAN B., et al.

Tuberkuloz ve Toraks , vol.73, no.1, pp.52-59, 2025 (ESCI, Scopus, TRDizin)

6. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye

Demir M., TUNAKAN DALGIÇ C., METE GÖKMEN E. N., SAVAŞ R., EROĞLU S., Ozden G., et al.

MEDICINA-LITHUANIA , vol.60, no.3, 2024 (SCI-Expanded, Scopus)

7. Characteristics of asthma in an older adult population according to sex and control level: why are asthma symptoms in older women not well-controlled?

KARADOĞAN D., YILMAZEL UÇAR E., YAVUZ Y., BAÇÇIOĞLU A., Oeztuerk A. B., Bozkurt N., et al.

JOURNAL OF ASTHMA , vol.61, no.6, pp.539-549, 2024 (SCI-Expanded, Scopus) Sustainable Development

8. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma

PAÇACI ÇETİN G., ARSLAN B., YILMAZ İ.

JOURNAL OF ASTHMA , vol.61, no.1, pp.20-26, 2024 (SCI-Expanded, Scopus)

9. The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma

ARSLAN B., PAÇACI ÇETİN G., YILMAZ İ.

JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY , vol.36, no.4, pp.189-209, 2023 (SCI-Expanded, Scopus)

10. Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma

YILMAZ İ., ÇETİN G. P., ARSLAN B., ŞEKER S., YILMAZ H. E. B., AKTAŞ E., et al.

Tüberküloz ve Toraks , vol.71, no.1, pp.75-93, 2023 (ESCI, Scopus, TRDizin)

11. Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?

ARSLAN B., PAÇACI ÇETİN G., Turk M., GÜLMEZ İ., YILMAZ İ.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.183, no.10, pp.1071-1077, 2022 (SCI-Expanded, Scopus)

12. Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma

YILMAZ İ., Çetin G. P., ARSLAN B.

Journal of Allergy and Clinical Immunology: In Practice , vol.10, no.7, pp.1935-1936, 2022 (SCI-Expanded, Scopus)

13. Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study

NAZİK BAHÇECİOĞLU S., TURK M., ATAYIK E., PAÇACI ÇETİN G., ARSLAN B., GÜLMEZ İ., et al.

ASTIM ALLERJI IMMUNOLOJI , vol.20, no.2, pp.81-86, 2022 (ESCI, Scopus, TRDizin)

14. Venom immunotherapy and difficulties encountered before and during immunotherapy: Double sensitization, systemic reactions, treatment with omalizumab, and high dose VIT

PAÇACI ÇETİN G., YILMAZ İ., Turk M., ARSLAN B., Bahcecioglu S. N.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.4, pp.1223-1234, 2022 (SCI-Expanded, Scopus, TRDizin)

15. Classification of asthma severity: Severe/not severe asthma or mild/moderate/severe asthma?

YILMAZ İ., Cetin G. P., ARSLAN B.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , vol.70, no.3, pp.300-301, 2022 (ESCI, Scopus, TRDizin)

16. The Management of Acute and Chronic Urticaria

YILMAZ İ., PAÇACI ÇETİN G., ARSLAN B., Turk M.

ASTIM ALLERJI IMMUNOLOJI , vol.20, no.3, pp.202-204, 2022 (ESCI, Scopus, TRDizin)

17. Are we entering an era of combined biologic use for severe asthma?

ARSLAN B., ŞEKER S., YILMAZ İ.

Tuberkuloz ve Toraks , vol.70, no.4, pp.403-404, 2022 (ESCI, Scopus, TRDizin)

18. Safety Profiles of Biological Therapies Used in Asthma Treatment

PAÇACI ÇETİN G., ARSLAN B., YILMAZ İ.

ASTIM ALLERJI IMMUNOLOJI , vol.20, no.3, pp.127-141, 2022 (ESCI, Scopus, TRDizin)

19. Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma

YILMAZ İ., Nazik Bahcecioglu S., Turk M., TUTAR N., PAÇACI ÇETİN G., ARSLAN B.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.4, pp.1953-1959, 2021 (SCI-Expanded, Scopus, TRDizin)

20. Blood hyperreosinophilia: A diagnostic challenge

PAÇACI ÇETİN G., KÖSE M., ARSLAN B., YILMAZ İ.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , vol.69, no.3, pp.408-415, 2021 (ESCI, Scopus, TRDizin)

21. Type 2 inflammation in asthma

YILMAZ İ., ARSLAN B.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , vol.69, no.1, pp.114-115, 2021 (ESCI, Scopus, TRDizin)

Metrics

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Citation (TrDizin)

H-Index (TrDizin)

Citation (Sobiad)

H-Index (Sobiad)

Citation (Sum Other)

Project

Open Access

UN Sustainable Development Goals

SDG 3: GOAL 3: GOOD HEALTH AND WELL-BEING

Publications & Works